Outlook Therapeutics is trading 5% up at $0.95 as investors step back in following a sharp two-day selloff that followed the FDA approval of its wet AMD therapy, LYTENAVA.
- The price action appears driven by bargain hunting and position rebalancing after significant profit-taking and volatility surrounding the July 27, 2026, approval milestone.
- The recovery is attributed to technical factors rather than new company-specific news, occurring while broader biotechnology sentiment remains soft.